NBTXR3 First in Class Radioenhancer
Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.
Only one administration
Fits into existing standard of care:
One product addressing areas of high unmet medical needs.
See moreRecent Press Releases
Nanobiotix Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
Nanobiotix to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
Nanobiotix announces 18.1 month median overall survival for 41 evaluable elderly and frail patients with HNSCC in phase I expansion evaluating NBTXR3 as a single agent activated by radiotherapy
ALL NANOBIOTIX PRESS RELEASES
Events
Meet Nanobiotix International events and conferences
JOIN US
“Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”
Anne-Juliette Hermant
Chief People Officer